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Summary
Common human malignancies acquire derangements of the translation initiation complex, eIF4F, but their functional
significance is unknown. Hypophosphorylated 4E-BP proteins negatively regulate eIF4F assembly by sequestering its mRNA
cap binding component eIF4E, whereas hyperphosphorylation abrogates this function. We found that breast carcinoma cells
harbor increases in the eIF4F constituent eIF4GI and hyperphosphorylation of 4E-BP1 which are two alterations that activate
eIF4F assembly. Ectopic expression of eIF4E in human mammary epithelial cells enabled clonal expansion and anchorage-
independent growth. Transfer of 4E-BP1 phosphorylation site mutants into breast carcinoma cells suppressed their tumori-
genicity, whereas loss of these 4E-BP1 phosphorylation site mutants accompanied spontaneous reversion to a malignant
phenotype. Thus, eIF4F activation is an essential component of the malignant phenotype in breast carcinoma.
Introduction transcriptional transactivation (Rosenwald et al., 1993; Johnston
et al., 1998) and positively modulate its activity by phosphoryla-
Genomic, transcriptional, and posttranslational regulatory tion through the Ras/MAPK kinase cascade (Waskiewicz et al.,
mechanisms of oncogenesis are well established in the pathobi- 1997).
ology of cancer. More recently, it has become evident that While phosphorylation of eIF4E changes eIF4F affinity for
cancer is subject to translational control (De Benedetti and Har- the transcript cap (Scheper et al., 2001), the primary regulation
ris, 1999; Zimmer et al., 2000; Hershey and Miyamoto, 2000). of assembly and integrity of eIF4F is exerted by three eIF4E
Protein synthesis is primarily regulated at the step of ribosome binding proteins (4E-BPs), designated 4E-BP1, -BP2, and -BP3
recruitment to the 5 mRNA terminus (Hershey and Merrick, (Lin et al., 1994; Pause et al., 1994). The predominant species
2000; Raught et al., 2000; Dever, 2002). The principal mode in most cells is 4E-BP1. The 4E-BPs compete with the eIF4Gs
for eIF4E using the same eIF4E binding motif (Tyr-X-X-X-X-of ribosome recruitment is association of the 43S ribosomal
complex with the m7G cap structure of transcripts and subse- Leu-0, where X varies and 0 indicates Leu, Met, or Phe) and
inhibit formation of eIF4F by sequestering eIF4E in a transla-quent ribosome scanning toward an initiation codon (Kozak,
1978, 1989). In mammals, this association is mediated by a tionally inactive complex (Mader et al., 1995). Growth and sur-
vival factors positively regulate assembly of the eIF4F complextrimeric complex, termed eIF4F, which consists of the large
scaffolding proteins eIF4Gs (eIF4GI and eIF4GII), the RNA heli- by promoting sequential phosphorylation of the 4E-BPs on six
serine/threonine sites through multiple Ras-dependent proteincase eIF4A, and the cap binding protein eIF4E (Gingras et al.,
1999b; Hershey and Merrick, 2000). The major target for modu- kinase cascades (Gingras et al., 1999a, 1999b, 2001; Mothe-
Satney et al., 2000; Herbert et al., 2002). Hyperphosphorylatedlation of cap-dependent translation by environmental and meta-
bolic signals is eIF4E. Extracellular stimuli resulting in cell cycle 4E-BP has a decreased affinity for eIF4E, resulting in its libera-
tion to initiate translation.transit or survival regulate eIF4E abundance by Myc-mediated
S I G N I F I C A N C E
There is a large body of clinical data documenting that carcinoma of the breast, lung, colon, and head and neck contain pathologi-
cally increased levels of translation initiation factors. In this report, we show that sustained activation of the protein synthesis initiation
machinery is sufficient to enable mammary epithelial cells to undergo clonal expansion and anchorage-independent proliferation
and is necessary for breast cancer cells to persist and form tumors. These data establish hyperactivation of the translation initia-
tion apparatus as part of the molecular strategy adopted by breast cancer cells to achieve autonomy and identify restoration of
physiological translational control as a new therapeutic objective.
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Elevated levels of eIF4E and eIF4GI are found in a broad
spectrum of transformed cell lines and human cancers and is
often associated with aggressive, poorly differentiated tumors
(reviewed by DeBenedetti and Harris, 1999; Zimmer et al., 2000;
Hershey and Miyamoto, 2000). Activation of eIF4F by ectopically
expressing eIF4E or eIF4GI transforms rodent fibroblasts (La-
zaris-Karatzas et al., 1990) and promotes development of lym-
phoma in the E-Myc model of mouse B cell lymphoma (Wendel
et al., 2004), and downregulation of eIF4F by increasing 4E-
BP1 reverts the malignant phenotype of transformed rodent
fibroblasts (Rousseau et al., 1996; Polunovsky et al., 2000).
Acquisition of autonomy for growth and survival signaling is
a crucial hallmark of advanced cancer (Hanahan and Weinberg,
2000). In this connection, overexpressed eIF4E confers resis-
tance to spontaneous and drug-induced apoptosis in a pleo-
tropic manner, including pretranslational and translational acti-
vation of the apoptosis antagonist Bcl-XL (Polunovsky et al.,
1996; Tan et al., 2000; Li et al., 2003). Along these lines, wild-
type 4E-BP1 sensitizes transformed rat fibroblasts to drug-
induced apoptosis (Polunovsky et al., 2000), and mutant forms
lacking key phosphorylation sites required for inactivation dis-
play significantly enhanced pro-apoptotic function (Li et al.,
2002). Although the burden of evidence strongly suggests a link
Figure 1. Analysis of the eIF4F translation complex in nontransformed andbetween the activity of the translation initiation apparatus and
malignant mammary epithelial cellshuman malignancy, the data in humans remain inferential.
A: Immunoblot showing steady-state levels of total and phosphorylatedTo directly examine the contribution of deregulated cap-
eIF4E, eIF4G1, and 4E-BP1 in cultures of actively proliferating nontransformed
dependent translation to the genesis and maintenance of human human mammary epithelial cells (HMECs, strain 184-A1) and in lines of breast
epithelial derived cancer, here we study the consequences of carcinoma cells.
B: Examination of eIF4F integrity. Cell lysates were incubated with 7-methyl-upregulating eIF4F in nontransformed human mammary epithe-
GTP-Sepharose resin to capture eIF4E and its binding partners. Cap boundlial cells and its inhibition in naturally occurring human breast
proteins were eluted with buffer containing 70 M 7-methyl-GTP, subjectedcarcinoma cells, and we establish a causal relationship between
to SDS-PAGE, transferred to nitrocellulose, and probed for eIF4E, eIF4GI, and
aberrant translational control and human breast carcinogenesis. 4E-BP1.
Results
Breast carcinoma cells display a hyperactivated 4E-BP1 revealed significant differences between immortalized
eIF4F complex HMECs and the breast carcinoma cell lines. In this analysis, the
Initiation of cap-dependent translation is governed by several tendency of available anti-4E-BP1 antibodies to bind nonspe-
factors: the abundance and phosphorylation status of eIF4E, cifically to many cellular proteins dictated a modification in the
the balance between cellular levels of the eIF4Gs and 4E-BPs, usual electrophoresis procedure (see Experimental Proce-
and the phosphorylation status of the 4E-BPs. We set out to dures). Cell extracts (50g/sample) were first boiled and cooled,
establish which of these events was associated with activation allowing the majority of cellular proteins to precipitate (4E-BP1
of cap-dependent translation in a series of breast cancer cell is heat stable and remains in solution) before standard SDS-
lines. Initially, we monitored expression levels of eIF4GI, eIF4E, PAGE and immunoblotting procedures were carried out. This
and 4E-BP1, abundance of phosphorylated eIF4E, and the abil- step precluded the use of the usual housekeeping proteins such
ity of eIF4E to associate with its binding partners in early pas- as actin as loading controls. The dominant form of 4E-BP1 in
sage human mammary epithelial cells (HMECs, strain 184, pop- nontransformed cells was the hypophosphorylated isoform 
ulation passage number 12) and in HMECs immortalized by represented by two distinct bands. In marked contrast, cancer
chemical mutagenesis (strain 184-A1, passage number 45) and cell extracts manifested only one  band and were enriched
found only marginal differences between these cell lines (data with slow migrating forms of 4E-BP1 (isoforms  and ). This
not shown). We concluded, therefore, that HMECs do not re- upward mobility shift reflects extensive phosphorylation of 4E-
quire changes in cap-dependent translation for immortalization. BP1, which markedly reduces its ability to sequester eIF4E
Next we compared the pattern of eIF4GI, eIF4E, and 4E- (Mothe-Satney et al., 2000; Gingras et al., 1999a). Thus, carci-
BP1 expression between immortalized HMECs and a panel of noma cells harbor alterations that activate eIF4E by increasing
breast carcinoma cell lines harboring diverse oncogenic alter- its association with eIF4GI, thereby favoring formation of intact
ations (Figure 1A). In contrast to previous reports (Kerekatte et eIF4F.
al., 1995; Antony et al., 1996), there were no significant differ- To directly compare the integrity of eIF4F in nontransformed
ences between nontransformed cells and carcinoma cell lines and malignant mammary epithelial cells, we assessed formation
with regard to the levels or phosphorylation status of eIF4E; of the m7GTP-eIF4E-eIF4G ternary complex in a cell-free test
instead, expression levels of eIF4GI were substantially increased system. Aliquots of the crude cell extracts used for immunoblot-
ting were incubated with agarose-immobilized m7GTP cap ana-in all breast cancer cell lines tested. Examination of the status of
554 CANCER CELL : JUNE 2004
A R T I C L E
Figure 2. Evasion of intrinsic apoptosis by breast
cancer cells is associated with increased eIF4F
and constitutive phosphorylation of 4E-BP1
A and B: Breast carcinoma cells were cultivated
in serum-deprived medium for 48 hr. Shown are
a representative histogram of DNA content (A)
and the relationship between apoptotic fre-
quency and quantity of eIF4G1 associated with
immobilized 7-methyl-GTP (B).
C: Western blot showing the 4E-BP1 isoform pro-
file in apoptosis-sensitive (MCF-7, SkBr, MBA-
MB-453) and apoptosis-resistant (MBA-MB-231,
MBA-MB-468) breast carcinoma cells after being
cultured in regular () or serum-deprived () me-
dium for 48 hr.
log to capture eIF4E and its binding partners the eIF4Gs and lines (MDA-MB-231 and MDA-MB-468) displayed the highest
4E-BPs; the levels of cap bound eIF4E, 4E-BP1, and eIF4GI levels of intact eIF4F, and regression analysis of the data re-
were analyzed by immunoblotting. The relative amounts of cap- vealed an exponential relationship between resistance to apo-
captured eIF4GI in cell extracts can serve as a cumulative indica- ptosis and the integrity of the eIF4F complex (Figure 2B).
tor of the integrity and functional potency of eIF4F, whereas Serum factors promote eIF4F assembly by stimulating path-
the amounts of cap-associated 4E-BP1 estimate the negative ways leading to phosphorylation of 4E-BPs (Gingras et al.,
impact of 4E-BP1 on eIF4F assembly. The cap bound fraction 1999b). We assessed expression of 4E-BP1 isoforms in the
from HMECs contained significant amounts of 4E-BP1 and very presence or absence of serum and found a clear downward
little eIF4GI (Figure 1B), indicating that in nontransformed cells, mobility shift in response to serum withdrawal in apoptosis-
cap-dependent translation is under strong 4E-BP1-mediated sensitive MCF-7 and SkBr3 cells and a bias toward hypophos-
negative control. In contrast, the cap bound complexes from phorylated species in serum-starved MDA-MB-453 cells, which
all carcinoma lines tested were enriched with eIF4GI, indicating exhibit a moderate susceptibility to apoptosis (Figure 2C). In
that cancer cells existed in a translationally activated state, contrast, MDA-MB-231 and MDA-MB-468, the cell lines least
supporting the argument that breast adenocarcinoma cells ac- sensitive to apoptosis, did not change their pattern of 4E-BP1
quire a set of metabolic and regulatory lesions that promote
expression, suggesting a constitutive mode of 4E-BP1 hyper-assembly of the eIF4F initiation complex.
phosphorylation. Thus, a sustained pattern of 4E-BP1 hyper-
phosphorylation and increased integrity of eIF4F in breast carci-Activation of eIF4F in breast cancer cells is associated
noma cells are associated with decreased dependence onwith resistance to apoptosis
extracellular survival signals.To evaluate the relationship between the status of eIF4F and
resistance to intrinsic pro-apoptotic signaling, we quantified
Activation of eIF4F enables immortalized mammaryapoptosis in breast carcinoma cells in the absence of serum
epithelial cells to form colonies on a plastic substratumsurvival factors. Flow cytometric analysis of cell viability indi-
and proliferate in an anchorage-independent fashioncated that serum-deprived MDA-MB-231 and MDA-MB-468
Immortalized 184-A1 HMECs do not form full-size anchorage-cells were markedly more resistant to apoptosis than SkBr-3,
MDA-MB-453, and MCF-7 (Figure 2A). The most resistant cell dependent colonies on a plastic substratum or exhibit anchor-
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Figure 3. eIF4E confers HMEC with the ability to
undergo anchorage-dependent and -indepen-
dent clonal proliferation
A: Characterization of experimental cell lines.
HMECs (strain 184-A1) were transduced with the
MSCV-M1GR1 retroviral construct encoding GFP
with or without 3HA-eIF4E, and subpopulations
of cells expressing the highest levels of GFP were
sorted by FACS. Shown are GFP fluorescence in
parental HMEC 184-A1 cells and in sorted 184-
A1/GFP/3HA-eIF4E cells (left) and eIF4E expres-
sion in sorted 184-A1/GFP and 184-A1/GFP/3HA-
eIF4E cells.
B: Effect of overexpressed eIF4E on HMEC 184-
A1 colony formation, cell cycle transit, and apo-
ptosis. Left: Parental HMEC 184-A1 or those trans-
duced with the indicated constructs were
seeded at a density of 500 cells/well into 6-well
clusters containing regular growth medium or
seeded into soft agar (20,000 cells/well), with cul-
tures continued for 2 weeks in MEBM. As a posi-
tive control, the growth pattern of MDA-MB-468
carcinoma cells is shown. Right: Exponential cul-
tures of mock transduced or HA-eIF4E-expressing
184-A1 cells were analyzed by flow cytometry.
Shown are the proportions of cells exhibiting hy-
podiploid (apoptotic) and S phase DNA content.
C: Functionally active 4E-BP1 reverses eIF4E-
dependent alterations in cell viability and
growth. 184-A1/3HA-eIF4E cells were stably trans-
fected with empty pACTAG-2-neo or with pAC-
TAG-2-neo encoding 4E-BP1wt or 4E-BP1 (which
lacks the eIF4E binding site). Left: Shown are ex-
amples of a representative immunoblots and
an anchorage-dependent clonogenic growth
assay. Right: Flow cytometric analyses of DNA
content (the means 	 SD for two experiments)
in 184-A1/3HA-eIF4E cells expressing 4E-BP1 wt or
. *p 
 0.001 compared to mock transduced
cells.
age-independent growth in soft agar. We therefore evaluated for the parental line and 184-A1/HA-eIF4E (Figure 3B, right).
This indicated that the predominant impact of eIF4E was tothe impact of sustained eIF4F activation on these hallmarks of
in vitro transformation. To achieve high levels of eIF4F activation reduce the frequency of apoptosis, rather than to increase cell
proliferation. However, despite acquiring the capacity to growin 184-A1 cells, we ectopically expressed eIF4E, its rate-limiting
component. The procedure employed replication-defective ret- in an anchorage-independent manner, the morphologic pattern
of 184-A1/HA-eIF4E cell growth was profoundly different fromrovirus containing a green fluorescent protein (GFP) gene linked
to a sequence encoding hemagglutinin (HA) epitope-tagged hu- that observed for breast carcinoma cells. MDA-MB-468 carci-
noma cells formed dense multilayer ovoid and spheroid struc-man eIF4E (HA-eIF4E). Cells expressing the highest levels of
GFP (the brightest 10% of the GFP-positive cell population) tures on a plastic substratum and in soft agar. In marked con-
trast, eIF4E-transduced HMECs formed flat colonies on plasticwere sorted using a FACSscan and propagated for further inves-
tigation (Figure 3A). and monolayer aggregates in agar with coherent nests and
trabeculae consisting of polygonal, closely attached cells withThe results were striking. Introduction of HA-eIF4E not only
enabled HMECs to form large colonies when adhering to a uniform nuclei. In addition, in stark contrast to highly tumorigenic
MDA-MD-231 or MDA-MB-468 cells, 184-A1/HA-eIF4E cellsplastic substratum, but also conferred the ability to proliferate
in soft agar (Figure 3B, left). Cytometric analysis of HMEC har- did not form tumors in nude mice at least during 20 days of
observation (not shown).boring ectopic eIF4E during exponential growth was carried out
to define their cell cycle distribution and viability. Compared Increased expression of 4E-BP1 reverses the eIF4E-induced
transformed phenotype in rodent fibroblasts, presumably byto mock transduced cells, there was a 50% decrease in the
proportion of hypodiploid (apoptotic) cells in 184-A1/HA-eIF4E, sequestration of overexpressed eIF4E (Rousseau et al., 1996).
Consequently, we examined whether elevated 4E-BP1 can re-whereas the proportion of actively proliferating cells was similar
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store the nontransformed phenotype in HMECs ectopically ex- effect of rapamycin on 4E-BP1 phosphorylation in MDA-MB-
468 cells (Figure 4A).pressing eIF4E. 184-A1/HA-eIF4E cells were transfected with
To determine whether the ability of rapamycin to inhibit 4E-a vector bearing a neomycin resistance cassette and sequences
BP1 phosphorylation was associated with its ability to modulateencoding HA-tagged wild-type 4E-BP1 or its 54–63 deletion
4E-BP1-induced apoptosis, MDA-MB-231 and MDA-MB-468mutant (4E-BP1), which lacks the eIF4E binding site and is
cells were engineered to express similar amounts of HA-4E-therefore unable to sequester eIF4E (Haghighat et al., 1995;
BP1 (Figure 4B). The resulting cells were serum-deprived in thePolunovsky et al., 2000). Both mock transfected 184-A1/eIF4E
presence or absence of rapamycin, and apoptosis was quanti-cells and cells bearing 4E-BP1 yielded full-size colonies on
fied. Rapamycin cooperated with ectopic 4E-BP1 in triggering
plastic after 14 days. In contrast, overexpression of wild-type
apoptosis in MDA-MB-231 cells, where it was active in blocking
4E-BP1 markedly decreased the clonogenic potency of eIF4E- 4E-BP1 phosphorylation. In marked contrast, rapamycin had
transduced cells. Cells co-expressing eIF4E and wild-type 4E- no impact on apoptosis in MDA-MB-468 cells, in which 4E-
BP1 were unable to form large colonies on a plastic substratum BP1 is phosphorylated in a rapamycin-insensitive fashion. Thus,
(Figure 3C, left), failed to grow in soft agar, and displayed a breast carcinoma cells may harbor alterations, which inactivate
modest but statistically significant reduction in the fraction of the pro-apoptotic activity of 4E-BP1 through hyperphosphoryla-
cells synthesizing DNA and a more than 2.5-fold increase in the tion. These results support previous findings that resistance of
frequency of apoptosis (Figure 3C, right). Thus, overexpressed human cancer cells to rapamycin can be associated with a
decrease in the antitranslational potency of 4E-BP1 (Dilling eteIF4E confers human epithelial cells with some properties char-
al., 2002).acteristic of malignant conversion. These include resistance to
The affinity of 4E-BP1 for eIF4E is governed by orderedintrinsic apoptosis and the ability to form anchorage-dependent
phosphorylation of critical amino acid residues and regulatedand -independent foci—properties that were antagonized by
through FRAP/mTOR signaling (Mothe-Satney et al., 2000; Gin-functionally active 4E-BP1.
gras et al., 2001). The presence of phosphates on sites T37
and T46, which are N-terminal to the eIF4E binding domain, is
4E-BP1 phosphorylation status determines its potency required for rapamycin-inhibitable phosphorylation of the
in suppressing breast cancer cell viability, C-terminal residues S65 and T70. To directly examine which of
proliferation, and colony-forming ability these phosphorylation sites on 4E-BP1 were required by breast
Breast carcinoma cells were characterized by activated eIF4F. cancer cells to suppress apoptosis, 184-A1 HMECs, MDA-MB-
Since 4E-BP1 decreased resistance to apoptosis and clono- 231, and MDA-MB-468 cells were infected with retroviral con-
genic capacity in HMECs with activated eIF4F, we reasoned structs encoding wild-type (4E-BP1wt) or phosphorylation site
mutant forms of HA-4E-BP1, and cells expressing identicalthat normalizing eIF4F in cancer cells by increasing 4E-BP1
amounts of GFP were sorted by FACS. Neither 4E-BP1wt nor itsshould also attenuate these aspects of the malignant pheno-
mutants increased apoptosis in nontransformed HMECs (Figuretype. However, when MDA-MB-231 and MDA-MB-468 cells
5A). In contrast, phosphorylation site mutants promoted apo-were engineered to express high levels of wild-type 4E-BP1,
ptosis in both the MDA-MB-231 and MDA-MB-468 cell lines.there was only a marginal impact on apoptosis and clonogenic-
The pro-apoptotic efficacy of 4E-BP1 mutants was site specific.ity. One explanation for this lack of sensitivity to the pro-apo-
In both carcinoma lines, expression of the A37/A46 and A70
ptotic activity of 4E-BP1 was that in cancer cells, the activity
mutants significantly increased apoptotic death, while mutating
of 4E-BP1 might be neutralized by extensive phosphorylation. S65 was less effective. The cell lines differed in that rapamycin-
We, therefore, examined whether pharmacological and/or ge- sensitive MDA-MB-231 cells displayed increased susceptibility
netic interventions that blocked 4E-BP1 phosphorylation would to mutating the T70 site, while the A37/A46 mutant was most
enhance the pro-apoptotic effect of overexpressed 4E-BP1 in active in promoting apoptosis in the rapamycin-resistant MDA-
cancer cells. MB-468 cells. Analysis of proliferative activity also revealed sup-
The multiple kinase cascades leading to 4E-BP1 phosphory- pression of cell cycle transit in cells expressing 4E-BP1 mutants,
with the A37/A46 mutant exerting a modest but statisticallylation include the Ras/PI3K/Akt/mTOR-mediated pathway (re-
significant antiproliferative effect in both cell lines tested (Figureviewed by Schmelzle and Hall, 2000; Rhoads, 1999; Raught et
5B). Ectopic expression of phosphorylation site mutants of 4E-al., 2001). This pathway can be activated by extracellular growth
BP1 in breast carcinoma cells (MDA-MB-231 and MDA-MB-factors through their cognate receptors, leading to phosphoryla-
468) tended to reduce their ability to form anchorage-dependenttion of 4E-BP1 in a FRAP/mTOR protein kinase-dependent fash-
colonies (Figures 5C and 5D), with the most profound effection (Gingras et al., 2001). We therefore examined the effects of
observed with 4E-BP1A37/A46 in MDA-MB-468 cells and with 4E-4E-BP1 phosphorylation on 4E-BP1-induced apoptosis in
BP170 in MDA-MB-231 cells.
MDA-MB-231 and MDA-MB-468 cells, using the FRAP/mTOR
To determine whether the observed alterations in cell death,
inhibitor rapamycin as a tool to suppress 4E-BP1 phosphory- proliferation, and colony-forming capacity in response to each
lation. In order to minimize the effects of extracellular phos- 4E-BP1 mutant was related to its potency in repressing the
phorylation and survival signaling, cells were pre-incubated in translational function of eIF4F, MDA-MB-468 cells were cotrans-
serum-free medium for 24 hr. Surprisingly, immunoblot analysis fected with wild-type or a mutant form of 4E-BP1 along with a
revealed that these cell lines differ profoundly in their response dicistronic reporter, which directs translation of Renilla lucifer-
to rapamycin. In MDA-MB-231 cells, rapamycin induced the ase in a strictly cap-dependent manner and mediates translation
expected 4E-BP1 mobility shift toward the faster migrating hy- of firefly luciferase via an IRES (Poulin et al., 1998; Li et al.,
2002). In accord with a potential causal link between the cellpophosphorylated species. In contrast, there was no detectable
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Figure 4. Concordance between 4E-BP1 phos-
phorylation and apoptosis in rapamycin-treated
breast carcinoma cells
A: MDA-MB-231 and MDA-MB-468 cells were se-
rum-deprived for 24 hr and continued in serum-
free DMEM for 24 hr in the presence or absence
of 100 nM rapamycin. Shown are immunoblots
illustrating the phosphorylation status of 4E-BP1.
B: MDA-MB-231 and MDA-MB-468 cells were
transduced with GFP/3HA-4E-BP1wt, and subpop-
ulations of each cell line expressing similar
amounts of 3HA-4E-BP1 were isolated by GFP
sorting and confirmed by HA-immunoblotting
(top). Sorted cells were serum deprived in the
presence or absence of rapamycin for 24 hr and
apoptosis was quantified by FACS. The mean 	
SD of three independent experiments is shown.
*p 
 0.001.
growth inhibiting and antitranslational activities of 4E-BP1, the 1.2 mm3/day and tumors arising from 4E-BP1A37/A46 cells grew
very slowly—only 3.5 	 0.7 mm3/day.most profound repression of cap-dependent translation ob-
served with 4E-BP1A37/A46 was associated with the greatest in- All tumors were excised after euthanasia on day 21. Histo-
pathological analysis revealed that tumors formed by cells har-crease in apoptosis and the greatest decreases in colony forma-
tion and BrdU incorporation (data not shown). boring 4E-BP1wt or 4E-BP1A37/A46 displayed increased cellular
and nuclear pleomorphism and had fewer blood vessels thanTo determine the maximum cell death response that could
be attained by overexpression of 4E-BP1 in apoptosis-resistant control tumors (Figure 6C). To evaluate cell population dynam-
ics, tumor cell proliferative and apoptotic indices were quanti-cancer cells, MDA-MB-468 cells expressing 4E-BP1A37/A46 were
iteratively transduced with sequences encoding GFP/4E- fied. Ectopic 4E-BP1 moderately suppressed tumor cell prolifer-
ative activity, as reflected by a 10% decrease in the number ofBP1A37/A46 with subsequent sorting of the brightest 10% of cells.
After three rounds of GFP/4E-BP1A37/A46 transduction, neither Ki-67-positive cells and a 30% decrease in mitotic index (Figures
6C and 6D). To assess the frequency of apoptosis, tissue wasGFP nor HA-4E-BP1 expression levels could be elevated further
(Figure 5E, top). Ectopic expression of maximum achievable analyzed using a TdT-mediated dUTP-digoxigenin nick end la-
beling (TUNEL) method. The apoptotic frequency was increasedlevels of 4E-BP1A37/A46 stimulated apoptosis in a dose-dependent
manner, with a plateau observed at about 12%–14% (Figure almost 7-fold in tumors arising from 4E-BP1wt cells and about
2-fold in tumors formed by 4E-BP1A37/A46 cells (Figures 6C and5E, bottom). This modest frequency of cell death could not be
increased further by serum withdrawal or by combining serum 6D). These data indicate that the major effect of 4E-BP1 on
tumor growth is by promoting apoptosis. Our data also docu-withdrawal and rapamycin. Thus, increased expression of 4E-
BP1 along with strategies that allow it to evade physiological ment a lesser but definite repression of tumor cell proliferation
by 4E-BP1, as well as a possible negative effect of 4E-BP1 onmechanisms of 4E-BP1 inactivation sensitized a limited cohort
of breast carcinoma cells to apoptosis. These findings suggest angiogenesis.
These data also uncovered a striking contradiction. Wild-that the aggregate impact of relatively modest decreases in
breast carcinoma cell viability and proliferation can lead to pro- type 4E-BP1 displayed low-level proapoptotic activity in MDA-
MB-468 cells in vitro but was highly potent in vivo. In contrast,found reductions in clonogenic capacity.
4E-BP1A37/A46 manifested high pro-apoptotic and anticlonogenic
potency in vitro but only modest activity in tumors. A clue toTumorigenicity of breast carcinoma cells is inhibited
the significance of these findings came from an examination ofby overexpressed 4E-BP1
tumor cell morphology. Cells ectopically expressing 4E-When MDA-MB-468 cells were implanted into mammary fat
BP1A37/A46 manifested a pattern of cell death that clearly differedpads of immunodeficient mice, they formed tumors with a la-
from those in 4E-BP1wt tumors. Most apoptotic cells in tumorstency period of 3 days and a diameter of 9.7	 0.8 mm (mean	
SEM) within 3 weeks (Figures 6A and 6B). In marked contrast, formed by 4E-BP1wt cells exhibited morphology typical for early
stages of apoptosis. In contrast, the TUNEL-positive cells inMDA-MB-468 cells expressing high levels of either 4E-BP1wt or
4E-BP1A37/A46 formed tumors with a much longer latency. Tumors tumors arising from 4E-BP1A37/A46 cells contained predominantly
compact apoptotic bodies—a morphological pattern typical offormed by 4E-BP1wt cells were first apparent at day 5, whereas
4E-BP1A37/A46-expressing cells formed visible tumors only after late-stage apoptotic degradation (Figure 6C). Based on this, we
considered the possibility that a cohort of HA-4E-BP1A37/A46 cells12 days. Control tumors grew at a rate 22.2 	 1.5 mm3/day
from day 13 to day 21 after implantation, whereas during the had already undergone apoptosis during the latent period and
that the relapsed tumors arose from those cells that escapedsame time period, tumors formed by 4E-BP1wt cells grew 11.8	
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Figure 5. Mutating phosphorylation sites en-
hances the pro-apoptotic and antiproliferative
activities of 4E-BP1 in breast carcinoma cells
A: Apoptosis in nontransformed HMECs and in
breast carcinoma cells expressing wild-type or
phosphorylation site mutants of 3HA-4E-BP1.
Nontransformed HMECs (strain 184-A1) and
breast carcinoma lines MDA-MB-231 and MDA-
MB-468 were transduced with each GFP/3HA-4E-
BP1 construct to be tested or empty GFP vector.
Cells were sorted to express similar amounts of
GFP and cultured for 48 hr in regular growth me-
dium, and apoptosis was quantified by flow cy-
tometry. *p 
 0.05 compared to mock trans-
duced cells.
B: Effect of wild-type and mutant 4E-BP1 on cell
proliferation. 4E-BP1-transduced cells were ex-
posed to 110 M BrdU for 16 hr in regular growth
medium. Incorporation of BrdU was quantified
using the BrdU assay kit (Roche) according to
the instruction provided by the manufacturer.
C: Effect of wild-type and mutant 3HA-4E-BP1 on
colony-forming ability of stably transduced MDA-
MB-231 cells. Expression of 3HA-4E-BP1 was con-
firmed by HA-immunoblotting (top), and 500
cells/well were seeded into 6-well clusters, with
cultures continued for 2 weeks in regular growth
medium. Colony formation was assessed by
Coomassie blue staining of fixed cells (bottom).
D: Colonies formed by MDA-MB-231 and MDA-
MB-468 cells stably expressing wild-type or mu-
tant 3H-4E-BP1 (500 cells per plate) were quanti-
fied. The means 	 SD for three experiments are
shown. *p
 0.05 compared to mock transduced
cells.
E: Relationship between expression levels of 4E-
BP1A37/A46 and apoptosis in MDA-MB-468 cells.
MDA-MB-468 cells were iteratively transduced
with GFP/3HA-4E-BP1A37/A46 in a step-wise fashion.
After each transduction step, the brightest 10%
of cells were collected by using a FACS sort-
ing procedure, and apoptosis frequencies
were quantified by flow cytometry. Shown are
HA-immunoblots after iterative transfer of GFP/
HA-4E-BP1 into MDA-MB-468 cells (top) and
apoptosis frequencies in transduced cells after
cultivation in regular growth medium, presented
as a function of 3HA-4E-BP1 expression level
(mean 	 SD, bottom).
apoptosis—presumably through the loss or inactivation of 4E- by loss of hypophosphorylated forms of 4E-BP1, and that the
regrowth of 4E-BP1A37/A46 tumors after a long latency resultedBP1A37/A46—due to strong selective pressure against this pro-
apoptotic protein. from loss of ectopic 4E-BP1 expression.
To examine this possibility experimentally, we traced ex-
pression of exogenous 4E-BP1wt and the phosphorylation sitePropagation of breast carcinoma cells selects for gain
of apoptosis resistance and decreased expression mutants in long-term cultures of nontransformed HMECs and
breast carcinoma cells. In HMECs, which resist the pro-apo-of hypophosphorylated 4E-BP1
To assess the association between ectopic expression of 4E- ptotic and antiproliferative effects of all forms of 4E-BP1 tested,
expression levels of ectopic 4E-BP1 were unchanged duringBP1 and tumor cell fate, tumors formed by 4E-BP1wt and 4E-
BP1A37/A46 cells were evaluated for HA-4E-BP1 expression by the entire 10 week period of observation (Figure 7B). In striking
contrast, MDA-MB-468 cells revealed a dramatic reduction inHA immunostaining. Both 4E-BP1wt and 4E-BP1A37/A46 tumors
revealed high levels of ectopic 4E-BP1, predominantly in the steady-state levels of the mutant forms of ectopic 4E-BP1—and
among these, 3HA-4E-BP1A37/A46 was nearly absent after 7–8regions where extensive cell death was observed (Figure 7A).
Of note, the expression of HA-4E-BP1 in viable cells of 4E- weeks of cultivation (Figures 7B and 7C). The loss of ectopic 4E-
BP1 expression in 3HA-4E-BP1A37/A46-transduced breast cancerBP1A37/A46 tumors was markedly reduced compared with that
found in tumors formed by 4E-BP1wt cells. This suggested the cells was closely associated with gain of resistance to apoptosis
and restoration of tumorigenicity. Thus, inactivation of the anti-possibility that the process of tumor formation indeed selected
for cells that evade apoptosis and/or aggressively proliferate translational function of 4E-BP1 by its hyperphosphorylation
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Figure 6. 4E-BP1 phosphorylation status deter-
mines its potency as an inhibitor of xenograft
tumor growth
MDA-MB-468 cells (5  106) transduced with ei-
ther 4E-BP1wt (4E-BP1wt) or phosphorylation site
double mutant (4E-BP1A37/A46) were injected into
the mammary fat pads of nude mice, and tumor
growth was evaluated after the time intervals
indicated.
A: Representative animals photographed at 21
days post injection. Arrows indicate loci where
cells were injected.
B: Quantification of tumor volume. The average
tumor volume for six animals from each cell line
tested was determined (mean 	 SE).
C: Histopathology of mouse fat pads after injec-
tion with 3HA-4E-BP1-expressing cells. Fat pad
samples were excised at the time of euthanasia.
Sections were stained with hematoxylin-eosin
(H/E, left) to elucidate tumor morphology or un-
derwent TUNEL staining to identify apoptotic cells
(middle) and Ki-67 immunostaining to reveal
proliferating cells (right). Representative micro-
scopic fields are shown. Arrows point to apo-
ptotic cells and arrowheads indicate apoptotic
bodies.
D: Proliferative and apoptotic indices in tumors
formed by 4E-BP1 and vector-transduced MDA-
MB-468 cell lines. The results represent mean
values 	 SE from 500 microscopic fields of three
tumors formed by cells expressing empty vector
or 3HA-4E-BP1. *p 
 0.05.
was an essential condition for efficient propagation of breast and Harris, 1999; Zimmer et al., 2000; Hershey and Miyamoto,
2000). Many known oncogenic factors are either upstream mod-carcinoma cells in vitro and for their tumorigenicity in the murine
xenograft model. These data are consistent with a scenario ulators of eIF4F integrity (e.g., HER-2/neu, EGF-R/erb-b, c-Myc,
etc.), or downstream effectors of eIF4F function (e.g., cyclin D1,whereby expansion of transformed cells during breast tumori-
genesis requires selection for durable activation of eIF4F as a Bcl-XL, etc.), or both (e.g., Ras) (Brown and Schreiber, 1996;
Rhoads, 1999). Thus, in naturally occurring breast cancer, eIF4Fpart of the program acquired by cancer cells to propagate and
persist. can plausibly serve as an integrator and amplifier of a broad
range of diverse proneoplastic signals emanating from mutated
cancer-related genes.Discussion
These observations, however, leave open the key question
of whether sustained activation of the translation initiation com-The existing paradigm for causality in cancer biology is that
plex eIF4F in cancer cells is essential for expression of a trans-cancer cells can acquire oncogenic alterations in one of two
formed phenotype or whether it is a secondary consequenceways. First, a gene directly controlling essential growth regula-
of the intrinsic need of cancer cells for increased protein synthe-tory events can itself be mutated, as occurs with the Ras V12
sis. In this report, we show that sustained gain of eIF4F functionmutations frequently found in lung cancer. Second, a group
causes a critical hallmark of cancer (i.e., self-sufficiency of hu-of genetic alterations—no one of which is obligatory—can act
man epithelial cells for clonogenic expansion) and that aberrantindirectly by modulating critical linchpin upstream regulators of
overexpression of eIF4F is essential for naturally occurring hu-an oncogene or a tumor suppressor gene. In the case of breast
man breast carcinoma cells expressing diverse oncogenic alter-cancer, ras is mutated in only about 5% of cases (Bos, 1989).
ations to persist and propagate in vitro and in vivo. We alsoNonetheless, breast cancer cells uniformly express activated
discovered that the strategies used by cancer cells to maintainRas by virtue of harboring one or more alterations in upstream
durable activation of eIF4F-mediated translation is more diversepathways converging on Ras (Olson and Marais, 2000). In this
than previously realized. In addition to increasing the expressionsituation, mammary epithelial cells acquire deregulated (onco-
levels of eIF4E, functional activation of eIF4F can occur bygenic) Ras—an essential component of the malignant pheno-
enhanced expression of eIF4GI and constitutive hyperphos-type—indirectly.
phorylation of 4E-BP1. These data indicate that aberrant cap-Does this same logic apply to the role of eIF4F integrity in
dependent translational control is a causal factor in both themalignant conversion of the mammary epithelium? A significant
genesis and maintenance of the malignant phenotype in humanbody of evidence links human cancer and activation of the cap-
dependent translational machinery (reviewed by De Benedetti mammary cancer.
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in any other growth state display much lower levels. In contrast,
expression of eIF4E in cancer cells is constitutively high, inde-
pendent of growth phase or density in culture. The growth state
of nontransformed cells in previous studies was not specified,
which we suspect accounts for the differences.
Our finding that 4E-BP1 hyperphosphorylation is part of the
strategy used by breast carcinoma cell lines to upregulate eIF4F
has not been previously observed in naturally occurring tumors.
Similarly, while overexpression of the eIF4Gs is not widely re-
ported in human tumors, in fact 30% of squamous lung carcino-
mas amplify the gene encoding eIF4GI (Brass et al., 1997).
Noteworthy is the fact that, like breast carcinomas, lung squa-
mous carcinoma cells do not overexpress eIF4E, whereas bron-
choalveolar carcinomas overexpress eIF4E but not eIF4GI (Ro-
senwald et al., 2001). Thus, cancer cells utilize a large repertoire
of mechanisms to promote the association of eIF4E with eIF4G.
Our findings support the idea of developing therapeutics that
correct aberrant activity of eIF4F. One advantage of focusing
attention on eIF4F as a novel target for anticancer therapy is
its pleotropism, residing near the apex of many well-defined
oncogenic growth and survival pathways. A second clear advan-
tage is the potential for achieving a wide therapeutic margin.
Since overexpressed 4E-BP1 does not preclude physiological
function of normal cells (Polunovsky et al., 2000), therapeutic
correction of aberrant cap-dependent translation has the poten-
tial to be well tolerated in patients with cancer. Finally, the
availability of detailed crystal structural data (Marcotrigiano etFigure 7. Loss of ectopic 4E-BP1 expression in breast cancer cells
al., 1997) may facilitate the development of small moleculesA: Immunohistochemical analysis of 3HA-4E-BP1 in tumors formed by MDA-
that can compete with capped mRNAs for binding to eIF4E andMB-468 cells expressing either 3HA-4E-BP1wt or 3HA-4E-BP1A37/A46. Sections of
tumors from day 21 were probed with anti-HA antibody, and signal was therefore be used to titrate cap- dependent translation in cancer
visualized with FITC-conjugated secondary antibody. Following antibody cells toward the normal (i.e., lethal) range.
staining, nuclei were counterstained with DAPI. Arrows indicate areas of
extensive cell death with high levels of FITC fluorescence.
Experimental proceduresB: 3HA-4E-BP1 expression during in vitro cultivation of MDA-MB-468 and 184-
A1 cells transduced with wild-type or phosphorylation site mutants of 3HA-
Cell lines and constructs4E-BP1. Extracts of transduced breast carcinoma cells and HMEC 184-A1
HMEC strains 184 and 184-A1 were kindly provided by Martha Stempferwere analyzed by HA immunobloting at the indicated time intervals after
(Lawrence Berkeley National Laboratory). The 184 cell strain was derivedtransduction.
from normal mammary tissue obtained at reduction mammoplasty (Stempfer,C: Loss of ectopic 4E-BP1 expression in 3HA-4E-BP1A37/A46 transduced breast
1985). Cells of this strain have a finite growth potential in culture. 184-A1carcinoma cells is associated with gain of resistance to apoptosis and resto-
ration of tumorigenicity. MDA-MB-468 cells transduced with HA-4E-BP1A37/A46 cells were obtained as immortalized derivatives of 184 cells after treatment
were seeded in regular growth medium, cultivated for 7 days (day 0 in the with benzo(a)pyrene (Stempfer, 1985). Both strains of HMECs were grown
plot, above), and subcultivated weekly thereafter at a 1:10 split ratio. After in chemically defined mammary epithelium basal medium (MEBM, Cambrex)
the indicated interval, cells were divided into three aliquots and were (1) supplemented growth factors. Breast carcinoma cell lines were obtained
examined for levels of 4E-BP1 by HA-immunoblotting, (2) subjected to flow from American Type Culture Collection (ATCC) and maintained in regular
cytometric quantification of apoptosis, or (3) injected into the mammary growth medium (Dulbecco’s modified Eagle’s high glucose [4.5 g/l] medium
fat pads of nude mice (six animals, 5  106 cells/injection) to assay tumor [DMEM, Sigma] supplemented with 10% fetal calf serum [FCS, Sigma], 100
latency (time interval after cell inoculation when tumors become visible in
units/ml penicillin, 100 units/ml streptomycin, and 125 ng/ml amphotericin
at least 50% of animals). The data from three independent experiments
[GIBCO]).are presented normalized to the percentage of values observed for each
Single and double 4E-BP1 phosphorylation mutants were describedparameter on day 0.
previously (Gingras et al., 1999a; Polunovsky et al., 2000). To obtain retroviral
constructs expressing tagged translational regulators linked to the GFP
reporter, both wild-type and mutant 4E-BP1 as well as human eIF4E se-
quences (Polunovsky et al., 1996; Tan et al., 2000) containing three amino-
To our surprise, steady-state levels of eIF4E were not higher terminal hemagglutinin (HA) tags (Polunovsky et al., 2000) were excised from
in breast carcinoma cells compared to nontransformed mam- pACTAG-2-3HA using Hind III and Apa I. Resulting fragments were blunted
mary epithelial cells. Although these results are in agreement using T4 DNA polymerase, and the gel-purified sequences were subcloned
into the retroviral expression vector MSCV-M1GR1 (Clontech), which en-with the findings of Raught et al. (1996) obtained in a murine
codes GFP to identify successfully transduced cells. The resulting vectorsmodel of breast cancer, they are at odds with earlier reports that
were sequenced in their entirety, and the coding regions used in thesehuman breast cancer cell lines overexpress eIF4E (Kerekatte et
experiments were found to be free of undesired mutations.al., 1995; Antony et al., 1996). One reasonable explanation for
this discrepancy is that eIF4E expression levels are extremely Cell transfection and retroviral transduction
sensitive to proliferative status in nontransformed cells. Cells in For stable transfection, 5  105 184-A1 cells expressing ectopic eIF4E were
midexponential growth, which was the case in our study, mani- seeded in 35 mm wells of 6-well clusters. After 24 hr, cells were transfected
with 1 g of the pACTAG-2 plasmid encoding the neomycin resistancefest levels of eIF4E comparable to cancer cells, whereas cells
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gene cassette and 3HA-tagged 4E-BP1 (either pACTAG neo/HA-4E-BP1wt S DNA content was determined on a FACSCalibur flow cytometer (Becton
Dickinson) with the CellQuest program.or pACTAG neo/HA-4E-BP1) using Lipofectamine 2000 reagent (Invitrogen)
according to the manufacturer’s instructions. Cells were incubated in the
Tumor formation, histology, immunohistochemistry,presence of Lipofectamine 2000 for 5 hr and switched to the appropriate
and TUNEL assaysgrowth medium containing 0.5 g/ml G418 for 2 weeks prior to use.
5  106 MDA-468 cells were suspended in 100 l of PBS and injected intoFor retroviral infection, cell monolayers (50% confluent) were incu-
the mammary fat pads of 4- to 5-week-old athymic female mice (BALB/bated in the presence of the retrovirus-containing supernatant and 8 g/ml
CanNCr-nu). At the time of injection, aliquots of cells were set aside forpolybrene (Sigma) for 48 hr. Infection frequencies based on GFP expression
immunohistochemistry and in vitro viability assays. Tumor growth was moni-were typically 25% to 30% for the HMEC 184-A1 strain, 95% to 98% for
tored by daily measurement. The time of initial tumor formation (the latencythe MDA-MB-468 cell line, and 30% to 45% for the other carcinoma lines.
period) was defined as the interval after cell inoculation when tumors becomeCell populations expressing different levels of the genes of interest were
visible in at least 50% of animals. Mice were sacrificed after 21 days ofobtained by first sorting infected cells according to GFP intensity at 488 nm
monitoring. Tumors were fixed in 4% paraformaldehyde at room tempera-laser emission using a Becton Dickinson FACS DiVa (BD Biosciences) with
ture, and tumor specimens were sent to the University of Minnesota Histopa-a 530/28 optical filter, followed by immunoblot assessment of the sorted
thology Laboratory Research Service for routine histological analysis (H/E),cell populations to assess expression of the gene of interest.
TUNEL staining, and Ki-67 immunohistohemistry. To identify the HA tag by
immunohistochemical staining, 4 m sections were deparaffinized, boiledImmunoblot analysis
with antigen unmasking solution for 10 min, incubated with anti-HA antibodyTo analyze the components of eIF4F, cells were lysed by three freeze-thaw
prelabeled with Alexa 488 fluorophore (Molecular Probes, 1:50) for 2 hr, andcycles, and equal amounts of cell extract protein per lane were subjected
counterstained for 20 min with DAPI (Sigma).to SDS-PAGE, blotted onto nitrocellulose membranes, and identified using
antibodies directed against eIF4E (mouse monoclonal antibody, 1:500,
StatisticsTransduction Laboratories), phospho-elF4E (rabbit polyclonal antibody,
Statistical analyses were performed using one-way analysis of variance1:1000, Cell Signaling), and eIF4G1 (rabbit polyclonal antibody, 1:4000, de-
(ANOVA) with Dunnett’s multiple comparison test (S-PLUS Guide to Statisti-veloped in the laboratory of N.S.). Actin immunoblotting (mouse polyclonal
cal and Mathematical Analysis, Version 4.0, Seattle, WA). A p value 
 0.05antibody, 1:500, Sigma) was performed as a loading control.
was considered significant. Results of flow cytometry were tabulated as theTo analyze endogenous and exogenous 4E-BP1, we followed estab-
mean 	 SD of 3–4 separate experiments. In each experiment, all conditionslished protocols (Pause et al., 1994; Gingras et al., 1999a) with minor modifi-
were examined in duplicate or triplicate. For analysis of tumorigenicity, mi-cations. Fifty micrograms of cell extract was boiled (100C, 7 min) and
totic and apoptotic indices are reported as the average number of eventsnon-heat-stable, precipitated cellular protein was removed by centrifugation
per 500microscopic field (quantified in 10 fields), and tumor weights (MDA-(13,000 rpm for 10 min). This step precluded the use of the usual housekeep-
MB-468/vector versus MDA-MB-468/4E-BP1wt and MDA-MB-468/4E-
ing proteins such as actin as loading controls. Resultant supernatant fluid
BP1A37/A46) were compared using a paired t test.
(enriched for heat-stable 4E-BP1) was subjected to SDS-PAGE, blotted onto
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